Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immuno-Oncology Outlook: Looking For Brain Cancer Options

Executive Summary

Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.

You may also be interested in...



Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Merck's Keytruda Gets Benefit Of Doubt, Despite Failing in Head & Neck

Prior PD-1 failures after accelerated approval include Roche's Tecentriq in bladder cancer.

Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC099062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel